theMednetRegister
Annals of oncology : official journal of the European Society for Medical Oncology 2019-08-01
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.   
ABSTRACT
BACKGROUND
Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.
PATIENTS AND METHODS
We conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation.
RESULTS
We studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2).
CONCLUSIONS
: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.

Related Questions

How would you approach frontline treatment of a patient with metastatic non-squamous NSCLC with ERBB2 amplification and PD-L1 > 50%?
In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?
New answer by Medical Oncologist at Perelman School of Medicine at the University of Pennsylvania (December 12, 2019)
Very erudite discussions by both @Karen L. Reckamp and @Balazs Halmos. I've very little to add. I just want to remind readers that this patient would have been eligible t...
Are you treating patients with RET-fusion+ metastatic NSCLC with RET inhibitors as the first line of therapy regardless of PD-L1 expression?
Are there scenarios in which you would proceed with checkpoint inhibitor for PDL1+ disease before having full molecular testing results?
New comment by Medical Oncologist at Conway Regional Health System ( April 18, 2023)
How would you approach if the patient developed grade 4 hepatotoxicity and that will not recover and had to wait for 3-4 weeks?
How do you approach patients with driver mutation positive, Stage IV NSCLC who don't benefit from upfront first-line TKI?
Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation...
New answer by Medical Oncologist at West Virginia University Cancer Institute (August 2, 2021)
It depends on the mutation. EGFR mutants after Osimertinib:- If oligometastatic disease: an option is radiation to the oligometastatic spots and continue osimertinib. It ...
Do you avoid immunotherapy in patients with Stage IV NSCLC with atypical EGFR mutations such as G719S or S768I?
New answer by Medical Oncologist at University of Colorado (October 20, 2021)
This is a difficult situation, but typically I would try to treat patients with an EGFR TKI (ideally in the context of a clinical trial) or with afatinib. Pooled data from the...
How would you approach treatment of a patient with metastatic NSCLC with PD-L1>1% and HER2-mutation?
Does this change for PDL1 1-49% vs >50%? Will you be more likely to employ other checkpoint inhibitors before use of HER2 targeting therapy? Or sta...
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (April 4, 2022)
HER2 alterations in non-small-cell lung cancer can include gene mutations (1%-4% of cases), gene amplifications (2%-5%) or protein overexpressions (2%-30%) which can lead to d...
What adjuvant therapy would you offer following adjuvant chemotherapy for a patient with Stage III lung adenocarcinoma with an atypical EGFR mutation such as EGFR L861R?
Would you offer adjuvant atezolizumab, osimertinib, or neither? Both IMpower010 and ADAURA only had patients with EGFR exon 19 deletion or L858R mutat...
New comment by Medical Oncologist at Onc San Antonio ( October 13, 2022)
Thank you Dr. @Anthony Bejjani for directing me to the old question- I should have checked that before. TheMednet is so helpful. Thank you Dr. @Tejas Patil for your comm...
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...
New comment by Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR ( February 25, 2024)
LAURA ‘overwhelmingly’ positive for PFS 
Copyright © 2024 theMednet
All Rights Reserved.